Education
About Us
Working with TipRanks
Follow Us
Allergy Therapeutics (AGYTF)
:AGYTF
AGYTF Stock Chart & Stats
$0.09
>-$0.01(-13.33%)
At close: 4:00 PM EST
$0.09
>-$0.01(-13.33%)
Day’s Range― - ―
52-Week Range$0.05 - $0.10
Previous CloseN/A
Volume5.00K
Average Volume (3M)0.00
Market Cap
$531.64M
Enterprise Value$332.66M
Total Cash (Recent Filing)$21.68M
Total Debt (Recent Filing)$44.52M
Price to Earnings (P/E)―
Beta-2.37
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,766,440,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)47.44
Price to Sales (P/S)3.19
P/FCF Ratio-4.95
Enterprise Value/Market Cap0.63
Enterprise Value/Revenue5.98
Enterprise Value/Gross Profit11.06
Enterprise Value/Ebitda-12.10
Forecast
1Y Price Target
$0.11Price Target Upside26.89% Upside
Rating ConsensusHold
Number of Analyst Covering0
Allergy Therapeutics News
AGYTF FAQ
What was Allergy Therapeutics’s price range in the past 12 months?
Allergy Therapeutics lowest stock price was $0.05 and its highest was $0.10 in the past 12 months.
What is Allergy Therapeutics’s market cap?
Allergy Therapeutics’s market cap is $531.64M.
When is Allergy Therapeutics’s upcoming earnings report date?
Allergy Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 131 days.
How were Allergy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Allergy Therapeutics overvalued?
According to Wall Street analysts Allergy Therapeutics’s price is currently Undervalued.
Does Allergy Therapeutics pay dividends?
Allergy Therapeutics does not currently pay dividends.
What is Allergy Therapeutics’s EPS estimate?
Allergy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Allergy Therapeutics have?
Allergy Therapeutics has 4,766,440,000 shares outstanding.
What happened to Allergy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allergy Therapeutics?
Currently, no hedge funds are holding shares in AGYTF
Allergy Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.11 (26.89% Upside)
$0.11 (26.89% Upside)
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.00%
12-Months-Change
Fundamentals
Return on Equity
-369.20%
Trailing 12-Months
Asset Growth
5.64%
Trailing 12-Months
Company Description
Allergy Therapeutics
Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.12% Other Institutional Investors
99.88% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---